UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000009447 |
|---|---|
| Receipt number | R000011099 |
| Scientific Title | Clinical prospective study to investigate efficacy of WT1 peptide (PepTivator(R))-pulsed dendritic cell vaccination therapy |
| Date of disclosure of the study information | 2012/12/01 |
| Last modified on | 2014/12/04 11:13:50 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Clinical prospective study to investigate efficacy of WT1 peptide (PepTivator(R))-pulsed dendritic cell vaccination therapy
Acronym
Clinical prospective study to investigate efficacy of WT1 peptide (PepTivator(R))-pulsed dendritic cell vaccination therapy
Scientific Title
Clinical prospective study to investigate efficacy of WT1 peptide (PepTivator(R))-pulsed dendritic cell vaccination therapy
Scientific Title:Acronym
Clinical prospective study to investigate efficacy of WT1 peptide (PepTivator(R))-pulsed dendritic cell vaccination therapy
Region
| Japan |
Condition
Condition
Malignant tumor (all HLA types)
Classification by specialty
| Medicine in general | Gastroenterology | Hepato-biliary-pancreatic medicine |
| Cardiology | Pneumology | Endocrinology and Metabolism |
| Hematology and clinical oncology | Nephrology | Surgery in general |
| Gastrointestinal surgery | Hepato-biliary-pancreatic surgery | Vascular surgery |
| Chest surgery | Endocrine surgery | Breast surgery |
| Obstetrics and Gynecology | Dermatology | Oto-rhino-laryngology |
| Urology | Oral surgery | Neurosurgery |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
To investigate efficacy of WT1 peptide (PepTivator(R))-pulsed dendritic cell vaccination therapy for malignant tumors.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Pragmatic
Developmental phase
Not applicable
Assessment
Primary outcomes
Immunological responses
Key secondary outcomes
Safety
Efficacy
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Vaccine | Maneuver |
Interventions/Control_1
WT1 peptide(PepTivator(R))-pulsed dendritic cells are injected on day0, day14, day28, day42, day56, day70
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
(1)Patients with histologically confirmed malignant tumors (all HLA types)
(2)Patients who recognized WT1 expression on tumor tissue
(3)Performance Status is 0-2
(4)No serious abnormality in bone marrow, liver, and renal functions
(5)Informed consent has been obtained.
Key exclusion criteria
Patients who have:
(1)Pulmonary fibrosis or interstitial pneumonia, or history or predisposition of them
(2)Serious drug allergy
(3)Positive for HIV or HTLV-1
(4)Active autoimmune disease
(5)Continuous systemic administration of steroids
(6)Other cancers
(7)Active infections
(8)Pregnant or lactating
(9)Serious cardiac disease
(10)Any reason why, in the opinion of the investigator, the patient should not participate.
Target sample size
5
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Takashi Kamigaki |
Organization
Seta Clinic Group
Division name
Clinical research center
Zip code
Address
Iidabashi 3-6-5 Kokoro to karada no genki plaza 8F, Chiyoda, Tokyo, 102-0072, Japan
TEL
03-5215-0086
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Hiroshi Ibe |
Organization
Seta Clinic Group
Division name
Clinical research center
Zip code
Address
Iidabashi 3-6-5 Kokoro to karada no genki plaza 8F, Chiyoda, Tokyo, 102-0072, Japan
TEL
03-5215-0086
Homepage URL
scrc@j-immunother.com
Sponsor or person
Institute
Seta Clinic Group
Institute
Department
Personal name
Funding Source
Organization
Medinet Co.,Ltd.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
瀬田クリニックグループ
Other administrative information
Date of disclosure of the study information
| 2012 | Year | 12 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Partially published
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2012 | Year | 09 | Month | 03 | Day |
Date of IRB
Anticipated trial start date
| 2012 | Year | 12 | Month | 01 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
AACR 2014/American Asociation for Cancer Research 2014
ISCT 2014/International Society for Cellular Therapy 2014
Management information
Registered date
| 2012 | Year | 11 | Month | 30 | Day |
Last modified on
| 2014 | Year | 12 | Month | 04 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011099
